Acumen Pharmaceuticals
Acumen Pharmaceuticals, Inc..
Launch date
Employees
Market cap
€142m
Enterprise valuation
(€69m) (Public information from Sep 2024)
Share price
$2.58 ABOS
Livermore California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.4m | - | - | - | - | - | - |
| % growth | (15 %) | - | - | - | - | - | - |
| EBITDA | (8.5m) | 61.6m | (45.1m) | (50.2m) | (89.3m) | (102m) | (117m) |
| % EBITDA margin | (592 %) | - | - | - | - | - | - |
| Profit | (7.3m) | (101m) | (42.9m) | (52.4m) | (81.9m) | (99.7m) | (87.8m) |
| % profit margin | (510 %) | - | - | - | - | - | - |
| EV / EBITDA | - | 1.3x | -2.0x | 1.1x | 0.2x | 0.5x | -1.3x |
| R&D budget | 8.0m | 12.3m | 32.4m | 42.3m | - | - | - |
| R&D % of revenue | 557 % | - | - | - | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$1.5m | Early VC | ||
| N/A | $20.0m | Series A | |
$730k | Grant | ||
| N/A | $3.6m | Grant | |
$15.0m | Series A | ||
$75.0m | Series B | ||
| N/A | $160m Valuation: $618m 430.4x EV/LTM Revenues -72.7x EV/LTM EBITDA | IPO | |
* | N/A | $130m | Post IPO Equity |
* | $50.0m | Debt | |
| Total Funding | €105m | ||
Related Content
Recent News about Acumen Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.